'Mounjaro,' Obesity Treatment, to Launch 15mg High-Dose Version in Korea Tomorrow
Supply of 12.5mg and 15mg Versions
High-dose versions of Mounjaro (active ingredient: tirzepatide), a treatment for diabetes and obesity, are set to launch in Korea.
According to the pharmaceutical industry on June 9, single-use prefilled pen versions of Mounjaro in 12.5mg and 15mg doses will be supplied in Korea starting the following day. Previously available doses included 2.5mg, 5mg, 7.5mg, and 10mg.
Eli Lilly's diabetes treatment Mounjaro (active ingredient tirzepatide). Eli Lilly
View original imageMounjaro has been approved in Korea as an adjunct to diet and exercise for improving blood sugar control in patients with type 2 diabetes, managing weight in patients who are obese or overweight, and treating obstructive sleep apnea.
The company stated that in a clinical study involving adults with obesity, after 72 weeks, the average weight loss was 16% in the 5mg group, 21.4% in the 10mg group, and 22.5% in the 15mg group.
Hot Picks Today
Already Expensive..."I Eat Two Eggs Every Morning—This Is Too Much": Early Heatwave Sparks Egg Price Fears
- "Wow, This Is Addictive": Justin Bieber's Wife Raves About 'Ddungbaratte'... Foreign Tourists Flock to K-Convenience Stores [K-Holic]
- "Exorbitant Food Prices" Beer Costs 30,000 Won per Glass... Locals Outraged Over Record Price Gouging at the World Cup [Current Affairs Show]
- "Youth Future Savings Account Offering Up to 19.4% Annual Interest Launches on June 22... Two-Week Enrollment Period"
- "Getting Your Hair Pulled and Kicked Is Routine... '9 Inmates Packed into 5 Pyeong' Cheongju Women's Prison, the Reality of Sweltering Heat [Reportage]"
Eli Lilly Korea believes the launch of these higher-dose products will offer new hope for patients who have struggled to achieve their treatment goals with the previously available dosages.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
